Ophthalmology Phase 1 Deal Benchmarks — Ex-US (2026)
Median upfront of $71M with total deal values reaching $713M in Ex-US territory.
Median Upfront
$71M
Total Deal Value
$492M
Royalty Range
5.3%–10.6%
Territory Multiplier
0.45x
Understanding Ophthalmology Deal Benchmarks at Phase 1
Phase 1 Ophthalmology licensing deals in Ex-US territory command a median upfront payment of $71M, with values ranging from $32M at the low end to $111M for premium assets. These benchmarks reflect the risk-adjusted value of clinical-stage assets in the ophthalmology therapeutic area, where development costs, competitive dynamics, and market potential all factor into deal pricing.
Total deal values — including milestones for development, regulatory, and commercial achievements — range from $271M to $713M, with a median of $492M. Royalty rates for ophthalmology assets at this stage typically fall between 5.3% and 10.6% of net sales, reflecting the balance between licensor value contribution and licensee commercialization investment.
The Ex-US territory applies a 0.45x multiplier to base deal economics. This accounts for market size, regulatory complexity, pricing environment, and competitive landscape differences across geographies. Licensors negotiating ex-us rights should calibrate upfront expectations and milestone structures accordingly.
Full Market Analysis
Detailed deal economics, territory impact analysis, and royalty structure breakdown.
Start 7-Day Free Trial$299/mo after trial · Cancel anytime
Full Benchmark Data
| Metric | Low | Median | High |
|---|---|---|---|
| Upfront Payment | $32M | $71M | $111M |
| Total Deal Value | $271M | $492M | $713M |
| Royalty Rate | 5.3% | — | 10.6% |
Comparable Deals
| Year | Licensor | Licensee | Upfront | Total Value | Deal Type |
|---|---|---|---|---|---|
| 2023 | Aldeyra Therapeutics | Partner | $50M | $350M | licensing |
| 2022 | Tarsus Pharmaceuticals | Samsung | $30M | $210M | licensing |
See All Comparable Deals
View 2 comparable Ophthalmology transactions with upfront payments, total values, and deal structures.
Start 7-Day Free Trial$299/mo after trial · Cancel anytime
Frequently Asked Questions
What is the average upfront payment for Phase 1 Ophthalmology deals in Ex-US territory?
How does Ex-US territory affect Ophthalmology deal value?
What royalty rates are typical for Phase 1 Ophthalmology licensing?
More Expert Insights
Royalty negotiation strategies and deal structure guidance.
Start 7-Day Free Trial$299/mo after trial · Cancel anytime
Related Benchmarks
$26M upfront
Ophthalmology · Preclinical · Ex-US
$223M upfront
Ophthalmology · Phase 2 · Ex-US
$613M upfront
Ophthalmology · Phase 3 · Ex-US
$1.6B upfront
Ophthalmology · Approved · Ex-US
$40M upfront
Oncology · Phase 1 · Ex-US
$34M upfront
Neurology/CNS · Phase 1 · Ex-US
$74M upfront
Immunology · Phase 1 · Ex-US
$103M upfront
Metabolic/Obesity · Phase 1 · Ex-US
Run Your Own Benchmark
These benchmarks are starting points. Get a customized valuation for your specific asset, indication, and deal structure.
Open SolidusCite This Data
Ambrosia Ventures. (2026). Ophthalmology Phase 1 Deal Benchmarks — Ex-US (2026). Retrieved from https://solidus.ambrosiaventures.co/data/ophthalmology-phase-1-deals-ex-us
<a href="https://solidus.ambrosiaventures.co/data/ophthalmology-phase-1-deals-ex-us">Ophthalmology Phase 1 Deal Benchmarks — Ex-US (2026)</a> — Ambrosia Ventures (2026)
<iframe src="https://solidus.ambrosiaventures.co/api/embed/chart?type=phase-upfront&ta=ophthalmology&theme=light" width="600" height="400" frameborder="0" style="border:1px solid #e2e8f0;border-radius:12px;"></iframe>
Data sourced from 1,600+ verified biopharma transactions. Updated monthly.